Alembic Pharmaceuticals gets nod from USFDA for Doxycycline Hyclate Tablets

05 Mar 2020 Evaluate

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxycycline Hyclate Tablets USP, 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Periostat Tablets, 20 mg of Galderma Laboratories, L.P. (Galderma).

Doxycycline Hyclate Tablets are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis. The company has a cumulative total of 119 ANDA approvals (107 final approvals and 12 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

839.50 -12.80 (-1.50%)
29-Dec-2025 14:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1715.00
Dr. Reddys Lab 1265.50
Cipla 1494.05
Zydus Lifesciences 904.20
Lupin 2081.80
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×